Anistreplase: Difference between revisions
Appearance
Content deleted Content added
m Dating maintenance tags: {{Cn}} |
Removing unsourced content |
||
Line 33: | Line 33: | ||
== Uses == |
== Uses == |
||
Anistreplase is used to treat [[blood clots]] in emergency situations such as [[myocardial infarction]].<ref name="pmid8563585">{{cite journal|author=Rawles J|date=27 January 1996|title=Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)|url=https://www.bmj.com/content/312/7025/212.full|journal=[[British Medical Journal]]|volume=312|issue=7025|pages=212–5|doi=10.1136/bmj.312.7025.212|pmc=2350007|pmid=8563585}}</ref> Early treatment gives better outcomes.<ref name="pmid8563585" /> |
Anistreplase is used to treat [[blood clots]] in emergency situations such as [[myocardial infarction]].<ref name="pmid8563585">{{cite journal|author=Rawles J|date=27 January 1996|title=Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)|url=https://www.bmj.com/content/312/7025/212.full|journal=[[British Medical Journal]]|volume=312|issue=7025|pages=212–5|doi=10.1136/bmj.312.7025.212|pmc=2350007|pmid=8563585}}</ref> Early treatment gives better outcomes.<ref name="pmid8563585" /> |
||
== Mechanism of action == |
|||
Anistreplase is a complex of purified human [[plasminogen]] and bacterial [[streptokinase]] that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts [[plasminogen]] to [[plasmin]], which in turn degrades fibrin ([[blood clot]]s) to fibrin split products.{{cn|date=December 2021}} |
|||
== History == |
== History == |
Latest revision as of 04:43, 21 July 2024
Clinical data | |
---|---|
Trade names | Eminase |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | 90 minutes |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Molar mass | approx. 131 kg/mol |
(verify) |
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
Uses
[edit]Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction.[1] Early treatment gives better outcomes.[1]
History
[edit]Anistreplase has been developed by Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.[1][2][3]
References
[edit]- ^ a b c Rawles J (27 January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". British Medical Journal. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585.
- ^ Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (April 1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317.
- ^ Rawles J, Light J (October 1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038.